Johnson & Johnson announced on 22 July that the FDA has granted De Novo marketing authorisation to OTTAVA, its robotic surgical system, for use in general surgery of the upper abdomen. The system's distinguishing feature is that its four arms are integrated into the operating table rather than mounted on booms or carts.
It is a real milestone in a market that has had one dominant player for two decades. It is also an announcement in which every substantive figure comes from the company, so we went through it claim by claim and checked what could be verified independently. Less than we expected.
What the release says, and what it is being reported as saying
| The claim | What the release actually says | What it rests on |
|---|---|---|
| Authorised for nine procedures | The word "nine" does not appear. The prose says "multiple procedures in general surgery, including" and then names ten | The release itself |
| 30–50% less space | Occupies "30–50% less space than traditional boom- and cart-mounted systems" | Internal Claims Support Documentation, September 2025 — not a published study |
| Rated for 2,460 cuts | Cutting performance "was evaluated by observing for deviations or defects after 900 cold and 2,460 hot cuts" | Internal Claims Support Documentation, November 2024 |
| FDA cleared it on 22 July | The release says the FDA "has granted" authorisation; 22 July is the announcement date | No FDA decision date is published yet |
Every substantive figure in this announcement is manufacturer-attributed. Two of the three performance claims cite unpublished internal documentation.
The most-repeated figure in early coverage — that the system was authorised for nine procedures — is not in the release. We searched both published versions for "nine" and found no occurrence. What the release says is "multiple procedures in general surgery, including", followed by ten named procedures.
That distinction matters in both directions. "Ten procedures" overstates the release, because "including" leaves the set open. "Nine" understates it and appears to originate downstream. The accurate formulation is that OTTAVA is authorised for multiple upper-abdomen general-surgery procedures, of which the company names ten.
| # | Procedure named in the release |
|---|---|
| 1 | Roux-en-Y gastric bypass |
| 2 | Gastrectomy |
| 3 | Cholecystectomy |
| 4 | Splenectomy |
| 5 | Gastric sleeve |
| 6 | Small bowel resection |
| 7 | Appendectomy |
| 8 | Lysis of adhesions |
| 9 | Fundoplication |
| 10 | Hiatal hernia repair |
Transcribed verbatim from the release, which introduces them with "including" — so this is what the company chose to name, not necessarily the full authorised set.
The two performance numbers both rest on unpublished documentation
The space claim — that OTTAVA "occupies 30–50% less space than traditional boom- and cart-mounted systems" — is footnoted to Johnson & Johnson's own OTTAVA Robotic Surgical System Claims Support Documentation dated September 2025, and qualified as "based on an evaluation of systems available as of September 2025". It is not attributed to a peer-reviewed or third-party study, and it names no competing product.
The scissors figure is more commonly misread. The release states that cutting performance "was evaluated by observing for deviations or defects after 900 cold and 2,460 hot cuts" — 3,360 cuts in total, of which 73% were hot. That is a description of a test volume, not a durability rating, and the sentence does not state the result. It does not say that no defects were found. Reporting it as "rated for 2,460 cuts" adds a claim the company did not make.
None of this is dishonest. The footnotes are present and the attribution is clear. But an internal claims-support document is not a checkable source, and a reader has no way to interrogate either number.
The FDA has not published anything yet
We checked the regulator directly rather than taking the announcement's word for it. The FDA's De Novo database was reachable and returned results normally; a device-name search for OTTAVA returns "No records were found", and a scan of all 486 records in the database finds no OTTAVA and no Johnson & Johnson entry matching it. The most recent decision published in that database is dated 17 July 2026, nine days before this article.
The openFDA API is also live and returns no matches across its 510(k), classification and registration datasets — and has no De Novo endpoint at all, so it could never carry this record regardless.
This is an absence of publication, not evidence of a problem. A lag of weeks to months before a De Novo record appears is ordinary, and the database's own most recent entry predates the announcement. The consequence for now is narrow and worth stating plainly: there is no independent DEN number, no FDA-published decision date, and therefore no way to confirm the scope of what was authorised except through the company's description of it.
| Date | Event | Source |
|---|---|---|
| Early 2025 | First cases in the IDE study completed | Company |
| Late 2025 | IDE approval for a US inguinal-hernia trial | Company |
| 7 Jan 2026 | De Novo application submitted to the FDA | Company |
| 22 Jul 2026 | Authorisation announced — 196 days later | Company |
| 3 Aug 2026 | Investor call, 8:00 a.m. ET | Company |
Every row is the manufacturer's own account. The FDA has published no record of this decision, so none of it is independently dated.
The elapsed time is the one figure here that is genuinely computable: 196 days from the 7 January submission to the 22 July announcement, or about six and a half months. De Novo is the pathway for a device with no existing predicate — the route that also establishes a new classification others can later use — and six months is brisk for it.
What to watch next
- The FDA record. When the De Novo entry publishes it will carry a DEN number, a decision date and the authorised indications for use — the first independent statement of scope.
- The 3 August investor call. Pricing, launch timing and installed-base plans are the questions the release does not answer.
- The inguinal hernia trial. The company says a US trial is ongoing. We could not locate a registration for it on ClinicalTrials.gov under the device or sponsor names we searched, so its enrolment and endpoints are not publicly checkable yet.
- Whether the space claim gets published. A 30–50% footprint reduction is the system's central design argument; a third-party measurement would settle it.
The caveats that matter
- Every performance claim here is the manufacturer's. We have verified what the release says, not whether it is right.
- We could not load an FDA page confirming the authorisation — because none exists yet, not because the FDA was unreachable. Both databases responded normally.
- The space claim is not a room-size claim. It describes the system's own footprint against boom- and cart-mounted systems; it says nothing directly about operating-theatre area, and converting it into one would be inventing a number.
- We have not evaluated clinical outcomes. Nothing in this article speaks to how the device performs in surgery.
- The elapsed-days figure is ours, computed from two company-stated dates.
Key takeaways
- What happened. J&J says the FDA granted De Novo authorisation to OTTAVA for upper-abdomen general surgery, announced 22 July 2026.
- The procedure count. The release says "multiple… including" and names ten. It never says nine.
- The performance claims. Both the 30–50% space figure and the 2,460-cut evaluation cite unpublished internal documentation.
- 2,460 is a test volume, not a durability rating — and the release does not state the outcome of that test.
- No independent record yet. Nothing for OTTAVA in the FDA De Novo database or openFDA; normal at four days, and the reason to treat the scope as company-described for now.
View author profile → · Editorial policy
